USTR is confirming earlier reports that there is an agreement in principle on pharmaceutical pricing between the US and UK.
The deal secured continued UK invested by UK pharmaceutical companies in the USDeal will strengthen supply chains a great job in the US.Administration is reviewing drug pricing practices of many other US trade partners.Deal calls for UK NHS to increase that price it pays for new medicines by 25%. US will refrain targeting UK pharmaceutical pricing practices and any future section 301 investigation
This article was written by Greg Michalowski at investinglive.com.